P-21 vs Dihexa
Side-by-side comparison of P-21 and Dihexa: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
P-21
Dihexa
P-21
P-21 (also written P021, or Peptide 021) is a synthetic peptidergic compound derived from the neurotrophic region of ciliary neurotrophic factor (CNTF), designed to activate neurogenic and BDNF-producing pathways in the…
Lowest listed price: $59.99 across 1 listing
Full P-21 profileDihexa
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models…
Lowest listed price: $79.99 across 3 listings
Full Dihexa profileSide-by-side comparison
| Attribute | P-21 | Dihexa |
|---|---|---|
| Category | Nootropics | Nootropics |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | P-21 is designed to engage a subset of CNTF's biological activity — specifically the neurogenic and BDNF-inducing effects — while avoiding the JAK/STAT3 activation on peripheral CNTF receptors that causes cachexia and muscle wasting when full-length CNTF is… | Dihexa is a small-molecule analog derived from angiotensin IV (AngIV). It retains the Tyr-Ile core of Nle1-AngIV, with an N-terminal hexanoic acid cap and a C-terminal 6-aminohexanoic amide that give it metabolic stability and blood-brain-barrier penetration.… |
| Half-Life | — | Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. |
| Typical Dose Range | 500-2000 mcg (0.5-2 mg) daily, most commonly 500-1000 mcg (community/self-experimentation range; no clinical validation) | 5 to 40 mg oral per day (anecdotal range; no established human dose) |
| Dosing Frequency | Once daily (some users divide into twice daily), typically dosed in the morning | Once daily (oral), typically in the morning |
| Administration | — | Oral, Intranasal, Subcutaneous |
| Side Effects | The side effect profile of P-21 in humans is not documented because no clinical trials have been conducted. Rodent studies describe generally acceptable tolerability at doses producing cognitive and neurogenic effects, without obvious signs of weight loss,… | No controlled human safety data. Anecdotal user reports include headache, fatigue, irritability or anxiety, insomnia, and vivid dreams, usually at higher doses. The most serious concern is theoretical rather than reported: because dihexa acts on the HGF/c-Met… |
| Molecular Weight | 578.67 g/mol (C27H42N6O8) | 504.7 g/mol |
| Common Vial Sizes | — | 50mg, 100mg |
Price tracking
Price tracking
P-21: potential benefits
- Enhanced hippocampal neurogenesis (preclinical)
- Improved learning and memory (preclinical, rodent)
- Elevated BDNF and other neurotrophin expression
- Neuroprotective effects in Alzheimer's disease models (preclinical)
- Reduced tau hyperphosphorylation and soluble amyloid-beta in transgenic mice (preclinical)
Dihexa: potential benefits
- Synaptogenesis: formation of new dendritic spines and functional synapses (preclinical)
- Memory and spatial-learning support in rodent models
- Potential research application in Alzheimer's and other neurodegenerative disease models
- HGF/c-Met and PI3K/Akt-linked neuroplasticity (mechanism proposed; key paper retracted)
Frequently asked
What's the difference between P-21 and Dihexa?
P-21 is a nootropics that p-21 is designed to engage a subset of cntf's biological activity — specifically the neurogenic and bdnf-inducing effects — while avoiding the jak/stat3 activation on peripheral…. Dihexa is a nootropics that dihexa is a small-molecule analog derived from angiotensin iv (angiv). it retains the tyr-ile core of nle1-angiv, with an n-terminal hexanoic acid cap and a c-terminal…. The two differ in mechanism, half-life (not reported vs Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.), and typical dose range.
Which has the longer half-life, P-21 or Dihexa?
P-21 has a half-life of not reported. Dihexa has a half-life of Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, P-21 or Dihexa?
Lowest listed price on BodyHackGuide: P-21 from $59.99, Dihexa from $79.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack P-21 and Dihexa?
Stacking depends on mechanism overlap, safety profile, and goals. P-21 and Dihexa should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy P-21 or Dihexa
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.